CTLA4 and cardiac arrhythmia: A comprehensive analysis of the FDA Adverse Event Reporting System highlighted that cardiac arrhythmias are a significant concern with ICIs, with anti-PD-1 and anti-PD-L1 therapies being associated with higher reports of arrhythmias compared to anti-CTLA-4 therapies.